NCT03658330

Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: VA Connecticut Healthcare System · Federal
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To evaluate if naltrexone plus ketamine is effective in reducing depression and alcohol consumption.

Detailed description

The primary goal of this proposal is to test naltrexone plus repeated ketamine treatment for major depressive disorder and alcohol use disorder in an open-label trial.

Conditions

• Major Depressive Disorder
• Alcohol Use Disorder

Interventions

Type	Name	Description
DRUG	Ketamine + Naltrexone	Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).

Timeline

• Start date: 2016-05-01
• Primary completion: 2016-10-01
• Completion: 2018-06-01
• First posted: 2018-09-05
• Last updated: 2018-09-07